Researchers at Oregon Health & Science University have made a groundbreaking discovery in animal models that a one-time treatment regimen can permanently clear HIV from newborns. The study's findings have the potential to advance quickly to human clinical trials, offering new hope for millions of people worldwide who require lifelong t...
SourceOregon Health & Science University·JournalNature Microbiology·TypeExperimental study·DateAug 10, 2026
AmScope B120C-5M Compound Microscope
AmScope B120C-5M Compound Microscope supports teaching labs and QA checks with LED illumination, mechanical stage, and included 5MP camera.
Scientists at La Jolla Institute for Immunology and Scripps Research have developed an HIV vaccine that trains immune cells to see past HIV's defenses. The vaccine resulted in the best HIV-fighting antibody response ever seen in primates, with human trials now underway.
SourceLa Jolla Institute for Immunology·JournalNature·TypeExperimental study·DateJul 6, 2026
Researchers found that Ebola virus can persist in cerebral organoids for up to 120 days, infecting various cell types, including neurons and astrocytes. The virus can trigger local inflammation and lead to disease relapses in survivors, highlighting the need for improved treatments.
SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalNature Microbiology·TypeExperimental study·DateJun 17, 2026
Scientists at La Jolla Institute for Immunology have characterized human antibodies capable of neutralizing measles virus. The new panel of human antibodies may form the basis for future medical therapies against measles infection, with a study showing a 500-fold lower viral load in a rodent model.
SourceLa Jolla Institute for Immunology·TypeExperimental study·DateMay 7, 2026
Apple iPhone 17 Pro
Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.
Researchers used AI to identify a new viral surface protein that triggers the production of neutralizing antibodies, offering a breakthrough for developing effective vaccines and antibody therapies. The discovery could also provide insights into treating smallpox, a related virus posing a bioterrorism risk.
SourceUniversity of Texas at Austin·JournalScience Translational Medicine·TypeExperimental study·DateDec 10, 2025
Researchers identified specific antibody features that limit Mtb growth, revealing critical insights into antibody-immune cell interactions. The study lays groundwork for potential antibody-based therapies or vaccines against tuberculosis, an urgently needed treatment for the deadly infectious disease.
SourceRagon Institute of MGH, MIT and Harvard·JournalImmunity·TypeExperimental study·DateMay 30, 2025
Scientists have engineered a monoclonal antibody that protects mice from a lethal dose of influenza A with sticky staying power. The new molecule combines specificity and broad binding capacity, adhering to the lung lining and blocking infection in mice.
SourceOhio State University·JournalNature Communications·DateMay 8, 2025
Scientists have developed the most broadly effective antivenom to date, neutralizing the neurotoxins of 19 deadly snakes including black mambas and king cobras. The antivenom combines protective antibodies and a small molecule inhibitor, offering a potential universal solution for snakebite victims.
SourceCell Press·JournalCell·TypeExperimental study·DateMay 2, 2025
Celestron NexStar 8SE Computerized Telescope
Celestron NexStar 8SE Computerized Telescope combines portable Schmidt-Cassegrain optics with GoTo pointing for outreach nights and field campaigns.
A new collaboration aims to develop an affordable and accessible monoclonal antibody therapeutic for CCHFV, treating thousands globally. USAMRIID discovered the antibody in mice, and LifeArc is supporting development of a fully humanized antibody.
SourceUS Army Medical Research Institute of Infectious Diseases·JournalScience Advances·TypeExperimental study·DateApr 23, 2025
Researchers developed a new, three times more effective version of the antibothropic serum used to treat snake venom poisoning. The improved serum had increased neutralizing antibodies and fewer proteins associated with side effects, resulting in greater potency and reduced risk of adverse reactions.
SourceFundação de Amparo à Pesquisa do Estado de São Paulo·JournalJournal of Proteome Research·DateApr 15, 2025
Researchers have made significant discoveries about the role of GP38 in viral infections and pathogenesis, highlighting its potential as a target for vaccines and medical countermeasures. Non-neutralizing GP38-specific antibodies have shown protective efficacy against lethal challenge, reducing circulating GP38 and vascular leak.
SourceUS Army Medical Research Institute of Infectious Diseases·JournalScience Translational Medicine·TypeExperimental study·DateApr 7, 2025
A study published in Human Gene Therapy found that over half of individuals with Niemann-Pick disease type C1 lacked neutralizing antibodies against AAV2 and AAV9. This absence of antibodies may impact the effectiveness of gene therapy treatments for this rare disorder.
SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalHuman Gene Therapy·TypeObservational study·DateMar 10, 2025
Researchers have identified powerful antibodies capable of neutralizing a wide range of norovirus strains, paving the way for designing a broadly effective norovirus vaccine. The discovery brings us closer to a vaccine that could provide lasting protection and prevent devastating effects of norovirus outbreaks.
SourceUniversity of Texas at Austin·JournalScience Translational Medicine·TypeExperimental study·DateMar 5, 2025
SAMSUNG T9 Portable SSD 2TB
SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.
A broadly neutralizing antibody has been shown to protect monkeys against severe H5N1 avian flu disease. The antibody's stable structure ensures it can withstand virus variants, providing universal protection against a globally spreading airborne infection. Serum levels of the antibody remained stable for up to 12 weeks.
SourceUniversity of Pittsburgh·JournalScience·DateJan 30, 2025
Researchers developed a nanoparticle-based vaccine that generates antibodies targeting conserved regions of sarbecovirus receptor-binding proteins, offering broader protection against multiple strains. The vaccine demonstrated strong antibody responses and protection in animal studies against diverse SARS-CoV-2 and other sarbecoviruses.
SourceMassachusetts Institute of Technology·JournalCell·DateJan 23, 2025
Researchers at NIH have identified a novel class of anti-malaria antibodies that target previously untargeted regions of the parasite. These antibodies have shown promise in providing protection against malaria parasites in animal models and could lead to new prevention methods.
SourceNIH/National Institute of Allergy and Infectious Diseases·JournalScience·DateJan 3, 2025
Sky-Watcher EQ6-R Pro Equatorial Mount
Sky-Watcher EQ6-R Pro Equatorial Mount provides precise tracking capacity for deep-sky imaging rigs during long astrophotography sessions.
A novel vaccine design has demonstrated robust immune response and broad neutralization of HCV strains in mouse models. The innovative approach employs epitope-focused immunogens, which could pave the way for an effective HCV vaccine, potentially limiting its global spread.
SourceUniversity of Lübeck·JournalScience Advances·TypeExperimental study·DateDec 6, 2024
Researchers have discovered a monoclonal antibody capable of targeting multiple SARS-CoV-2 variants, including recent Omicron strains. K4-66's exceptional ability to adapt to the virus's frequent mutations makes it a promising candidate for vaccine and therapy development.
SourceKumamoto University·JournalEBioMedicine·TypeExperimental study·DateDec 1, 2024
Researchers at Fred Hutchinson Cancer Center have made a breakthrough in understanding how protective antibodies can target malaria parasites. By analyzing the structure of these antibodies and their interaction with the parasite's protein, the team has identified a weak spot that could be targeted by vaccines to prevent severe disease.
SourceFred Hutchinson Cancer Center·JournalNature·TypeExperimental study·DateNov 20, 2024
Researchers found that repeated mRNA vaccines enhance mucosal antibodies in nasal secretions, blocking viral entry and providing sustained protection. The immune responses generated by mRNA vaccines may persist longer than previously thought, offering hope for sustained protection against emerging COVID-19 variants.
SourceVlaams Instituut voor Biotechnologie·JournalScience Translational Medicine·TypeObservational study·DateOct 23, 2024
Davis Instruments Vantage Pro2 Weather Station
Davis Instruments Vantage Pro2 Weather Station offers research-grade local weather data for networked stations, campuses, and community observatories.
Researchers at MIT found that a two-dose schedule for an HIV vaccine can generate a strong response to the virus, outperforming a traditional seven-dose regimen. The first dose primes the immune system, helping it to produce antibodies more effectively when a larger dose is administered one week later.
SourceMassachusetts Institute of Technology·JournalScience Immunology·DateSep 20, 2024
Researchers at the University of Montreal Hospital Research Centre have discovered that metformin can help deplete and eliminate viral reservoirs in people living with HIV. Metformin inhibits the mTOR molecule, slowing down HIV replication and reducing chronic inflammation.
SourceUniversity of Montreal Hospital Research Centre (CRCHUM)·JournaliScience·TypeExperimental study·DateSep 10, 2024
Researchers developed a monoclonal antibody called SC27 that targets multiple parts of the SARS-CoV-2 spike protein, including conserved sections. The antibody shows promise against various COVID-19 variants and related coronaviruses, potentially benefiting immunocompromised patients
SourceTexas Biomedical Research Institute·JournalCell Reports Medicine·DateSep 6, 2024
Researchers at UT Austin have developed a broadly neutralizing plasma antibody called SC27 that can neutralize all known COVID-19 variants. This discovery was made possible by the technology of Ig-Seq, which provides a closer look at the antibody response to infection and vaccination.
SourceUniversity of Texas at Austin·JournalCell Reports Medicine·DateSep 3, 2024
Fluke 87V Industrial Digital Multimeter
Fluke 87V Industrial Digital Multimeter is a trusted meter for precise measurements during instrument integration, repairs, and field diagnostics.
Researchers at Georgia State University have developed a new antibody therapy using llama-derived nanobodies that can broadly neutralize numerous strains of HIV-1. The nanobodies mimic the recognition of the CD4 receptor, offering unprecedented neutralizing abilities and potential for single-molecule treatment.
SourceGeorgia State University·JournalAdvanced Science·TypeExperimental study·DateJul 17, 2024
Researchers have developed a humanized mouse model with a fully functional human immune system, enabling the study of immunotherapy development, disease modeling, and vaccine development. The new model, called TruHuX, mounts specific antibody responses and can develop full-fledged systemic lupus autoimmunity.
SourceUniversity of Texas Health Science Center at San Antonio·JournalNature Immunology·TypeExperimental study·DateJul 5, 2024
Researchers have discovered how a neutralizing antibody blocks measles virus infection by arresting the fusion process. The study's findings may also be relevant to other viruses with pandemic potential, such as Nipah and parainfluenza viruses.
SourceLa Jolla Institute for Immunology·JournalScience·TypeExperimental study·DateJun 27, 2024
GQ GMC-500Plus Geiger Counter
GQ GMC-500Plus Geiger Counter logs beta, gamma, and X-ray levels for environmental monitoring, training labs, and safety demonstrations.
Researchers have successfully stimulated animals' immune systems to induce rare precursor B cells that can produce HIV broadly neutralizing antibodies. The findings are an encouraging step in developing a preventive HIV vaccine, targeting the challenging task of genetically diverse HIV.
SourceNIH/National Institute of Allergy and Infectious Diseases·JournalNature Immunology·DateMay 30, 2024
Researchers at La Jolla Institute for Immunology found that people who experienced breakthrough COVID-19 infections develop T cells better equipped to recognize and target SARS-CoV-2. The study also discovered that B cells produce more diverse antibodies targeting common epitopes between the vaccine and variants.
SourceLa Jolla Institute for Immunology·JournalCell Reports Medicine·TypeExperimental study·DateMay 24, 2024
Researchers found that repeat COVID-19 vaccinations elicit cross-reactive neutralizing antibodies capable of targeting multiple SARS-CoV-2 variants and distantly related coronaviruses. The findings suggest periodic re-vaccination may help build a stock of protective antibodies against emerging variants.
SourceWashU Medicine·JournalNature·TypeExperimental study·DateMay 17, 2024
Sony Alpha a7 IV (Body Only)
Sony Alpha a7 IV (Body Only) delivers reliable low-light performance and rugged build for astrophotography, lab documentation, and field expeditions.
A team of scientists has developed a novel vaccine approach that induces long-lasting protective immunity against SARS-CoV-2 virus in pre-clinical models. The Clec9A-RBD antibody construct targets specific dendritic cells, leading to exceptional durability of immune responses and potential to address shortcoming of current mRNA vaccines.
SourceNational University of Singapore, Yong Loo Lin School of Medicine·JournalMolecular Therapy·TypeRandomized controlled/clinical trial·DateMay 6, 2024
Researchers found that T cells and memory B cells provide durable protection against symptomatic SARS-CoV-2 infection, with levels attainable after two doses of mRNA vaccination. The study suggests a two-dose vaccination regimen for children against COVID-19.
SourceNational University of Singapore, Yong Loo Lin School of Medicine·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateMay 2, 2024
A Brazilian study found that a major bivalent COVID-19 vaccine induces neutralizing antibodies against the original coronavirus strain and subvariants of omicron. The vaccine's effectiveness was confirmed, but its importance in controlling disease was limited by its focus on the original strain.
SourceFundação de Amparo à Pesquisa do Estado de São Paulo·JournalJournal of Medical Virology·DateApr 25, 2024
Researchers have developed a DNA vaccine against zika virus that induces a strong immune response and protects mice from the virus. The vaccine uses genetic engineering to encode specific viral proteins and stimulates an adaptive immune response, with high levels of neutralizing antibodies produced.
SourceFundação de Amparo à Pesquisa do Estado de São Paulo·JournalFrontiers in Immunology·DateApr 18, 2024
Apple AirPods Pro (2nd Generation, USB-C)
Apple AirPods Pro (2nd Generation, USB-C) provide clear calls and strong noise reduction for interviews, conferences, and noisy field environments.
A Swedish study reveals that neutralising antibodies to the monkeypox virus decline significantly after two doses of the MVA-BN vaccine within the first month. The findings suggest that a booster dose may be necessary to maintain immunity, emphasizing the need for scientific evidence before policy decisions are made.
SourceEuropean Society of Clinical Microbiology and Infectious Diseases·DateMar 30, 2024
A study published in Immunity identified key findings from a patient who cleared hepatitis C, revealing new insights into the development of a vaccine. The researchers found that this individual's antibodies targeted multiple regions of the virus, suggesting a potential approach to elicit a stronger immune response.
Researchers found that initial vaccinations against the ancestral SARS-CoV-2 strain shape immune responses to newer variants BA.5 and XBB, with higher B cell repertoire leading to more effective cross-reactive immunity. This 'immunological imprinting' effect could impact future vaccine designs.
SourceUniversity of Pennsylvania School of Medicine·JournalImmunity·DateMar 14, 2024
Creality K1 Max 3D Printer
Creality K1 Max 3D Printer rapidly prototypes brackets, adapters, and fixtures for instruments and classroom demonstrations at large build volume.
A recent study found that newer monovalent COVID vaccines generated higher levels of antibodies against a range of Omicron variants, including the XBB and BQ.1.1 strains. The researchers also discovered that these vaccines increased mucosal antibody production, but not neutralizing antibody levels in the nasal cavity.
SourceThe Francis Crick Institute·JournalThe Lancet·TypeObservational study·DateMar 11, 2024
Researchers discovered an antibody that can block deadly toxins in snakes found throughout Africa, Asia, and Australia. The antibody protects against multiple snake species and has the potential to be used as a universal antivenom.
SourceScripps Research Institute·JournalScience Translational Medicine·DateFeb 21, 2024
Researchers at Dartmouth's Geisel School of Medicine and Thayer School of Engineering have made significant breakthroughs in understanding how antibodies combat herpes simplex virus (HSV) infections. The study reveals that antibody effector functions play a critical role in protecting against HSV, which may lead to new treatments for n...
SourceThe Geisel School of Medicine at Dartmouth·JournalCell Reports Medicine·TypeExperimental study·DateFeb 12, 2024
Researchers found a four-fold increase in immune response when people alternate arms during two-dose vaccinations. The study showed improved immunity to the original and omicron variants after three weeks and persisted beyond 13 months.
SourceOregon Health & Science University·JournalJournal of Clinical Investigation·DateFeb 6, 2024
Researchers at Duke University have discovered a critical structure on the HIV virus that plays a crucial role in its infection process. By understanding this structure's dynamics, scientists may be able to design broadly neutralizing antibodies for an AIDS vaccine.
SourceDuke University·JournalScience Advances·TypeObservational study·DateFeb 2, 2024
CalDigit TS4 Thunderbolt 4 Dock
CalDigit TS4 Thunderbolt 4 Dock simplifies serious desks with 18 ports for high-speed storage, monitors, and instruments across Mac and PC setups.
Researchers created a DNA-based vaccine that mimics the structure of a virus, inducing a strong antibody response against SARS-CoV-2. The vaccine uses a DNA scaffold carrying viral proteins, allowing the immune system to focus on the target antigen.
SourceMassachusetts Institute of Technology·JournalNature Communications·DateJan 30, 2024
Research reveals memory T cells formed after Omicron breakthrough infection provide enhanced immunity against future variants. The study suggests the immune system adapts to combat emerging strains, leading to higher chances of inducing memory T cell defenses.
SourceInstitute for Basic Science·JournalScience Immunology·TypeExperimental study·DateJan 19, 2024
Three different HIV antibodies independently protected monkeys from acquiring SHIV, providing statistically significant protection and dose-dependent effect. The findings support the HIV fusion peptide as a promising preventive vaccine target.
SourceNIH/National Institute of Allergy and Infectious Diseases·JournalScience Translational Medicine·DateJan 17, 2024
Researchers are exploring 'priming, shaping, and polishing' techniques to develop an HIV vaccine targeting rare immune cells that produce broad-neutralizing antibodies. The Amsterdam UMC-led project aims to create an effective vaccine for low- and middle-income countries with a €4.5m grant.
Researchers at Duke-NUS Medical School have discovered a potential intranasal vaccine candidate that provides improved, longer-lasting immunity against COVID-19. The vaccine boosts mucosal antibody response and enhances long-term immune protection through preferential induction of airway-resident T cells and central memory T cells.
SourceDuke-NUS Medical School·JournalEBioMedicine·TypeExperimental study·DateJan 9, 2024
Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C)
Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C) keeps Macs, tablets, and meters powered during extended observing runs and remote surveys.
The Pirola variant of SARS-CoV-2 has rediscovered an entry pathway into lung cells that was previously used by earlier variants, which may promote the development of pneumonia. The virus uses the cellular enzyme TMPRSS2 for entry and is resistant to most therapeutic antibodies.
SourceDeutsches Primatenzentrum (DPZ)/German Primate Center·JournalCell·TypeExperimental study·DateJan 9, 2024
The BA.2.86 omicron subvariant can infect human lung cells more efficiently than previous omicron variants, raising concerns about potential severe disease symptoms. While bivalent mRNA vaccines can neutralize BA.2.86, the efficiency is reduced, emphasizing the importance of getting a newer booster vaccine.
SourceOhio State University·JournalCell·DateJan 8, 2024
Scientists have developed a new system to display epitopes in mammal cells for immunization studies, potentially speeding up the immunization process. This method allows for targeted immune responses against specific viral proteins without the need to purify antigens.
SourceOxford University Press USA·JournalBiology Methods and Protocols·TypeExperimental study·DateDec 12, 2023
Rigol DP832 Triple-Output Bench Power Supply
Rigol DP832 Triple-Output Bench Power Supply powers sensors, microcontrollers, and test circuits with programmable rails and stable outputs.
Researchers found that a breakthrough infection builds upon existing memory B cell pool and introduces random mutations that prepare antibodies for new variants. Broad neutralizing antibodies can neutralize all tested Omicron variants.
SourceUniversity of Cologne·JournalImmunity·TypeObservational study·DateDec 7, 2023
A study of over 2,300 patients found that HIV-1 neutralizing antibody response decreases over time but highly potent broadly neutralizing antibodies remain detectable. This finding suggests a possible permanent vaccine response and is an important step toward developing an effective HIV-1 vaccine.
SourceUniversity of Cologne·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateNov 14, 2023
Researchers have discovered highly effective antibodies against P. aeruginosa that can block its type III secretion system and are effective against highly resistant bacteria. These 'pathoblockers' offer a potential therapeutic approach for treating acute and chronic infections with multi-resistant pathogens.
SourceUniversity of Cologne·JournalCell·TypeExperimental study·DateNov 2, 2023
Researchers at Duke University developed an innovative antibody approach to target and kill tumor-promoting molecules found in cancer cells. The study revealed notable reductions in tumor growth and minimal side effects, making it a promising new treatment option for various types of cancer.
SourceDuke University·JournalImmunity·TypeExperimental study·DateOct 30, 2023
Kestrel 3000 Pocket Weather Meter
Kestrel 3000 Pocket Weather Meter measures wind, temperature, and humidity in real time for site assessments, aviation checks, and safety briefings.
Scientists have developed a trivalent vaccine candidate that provides broad and long-lasting protection against COVID-19 infection by delivering the vaccine via the nose. The vaccine triggers a strong neutralizing antibody response and protects mucosal areas, preventing disease symptoms.
SourceOhio State University·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateOct 2, 2023
A new SARS-CoV-2 variant Eris has been detected, showing an advantage in evading neutralizing antibodies and increasing infectivity. The study found that Eris is less effectively neutralized by antibodies present in the blood of vaccinated individuals or those with a previous infection.
SourceDeutsches Primatenzentrum (DPZ)/German Primate Center·JournalThe Lancet Infectious Diseases·TypeExperimental study·DateSep 14, 2023
New SARS-CoV-2 variants, such as BQ.11 and XBB.1.5, bind to cells more tightly and evade antibodies more efficiently than earlier variants, allowing reinfections and breakthrough infections. Previous infection or vaccination can generate antibodies that recognize some proteins on newer variants, reducing the risk of serious illness.
SourceUniversity of Washington School of Medicine/UW Medicine·JournalNature·TypeExperimental study·DateAug 30, 2023
Pregnant individuals who received a full course of COVID-19 vaccination and a booster have the strongest immune protection from the disease. Boosting after previous infection increases antibody levels in both mothers and newborns, providing maximum possible protection to infants as SARS-CoV-2 evolves.
SourceWeill Cornell Medicine·JournalNature Communications·DateAug 10, 2023
DJI Air 3 (RC-N2)
DJI Air 3 (RC-N2) captures 4K mapping passes and environmental surveys with dual cameras, long flight time, and omnidirectional obstacle sensing.
Researchers have identified a family of broadly neutralizing antibodies targeting the HIV-1 envelope protein, which may contribute to long-term remission from infection. These antibodies were found to induce the elimination of infected cells and impose a selective pressure on the virus, paving the way for new therapeutic approaches.
SourceInstitut Pasteur·JournalCell Host & Microbe·DateAug 8, 2023
A new adjuvanted intranasal vaccine has shown promise in protecting both young and old mice against SARS-CoV-2 infection. The vaccine combines an RNA-based molecule with a nanoemulsion, resulting in a strong immune response.
SourceMichigan Medicine - University of Michigan·Journalnpj Vaccines·DateAug 4, 2023